Dextromethorphan is a widely used antitussive agent, also showing increased recreational abuse. Dextromethorphan and its metabolite dextrorphan are non-competitive antagonists at the N-methyl-d-aspartate (NMDA) receptor ion channel. Single doses of some NMDA receptor antagonists produce neuropathologic changes in neurons of the retrosplenial/posterior cingulate cortices (RS/PC), characterized by vacuolation or neurodegeneration. To determine whether dextromethorphan produces these characteristic lesions, dextromethorphan was administered orally either as a single dose of 120mg/kg to female rats, or daily for 30 days at doses of 5-400 mg/(kg day) to male rats and 5-120mg/(kg day) to female rats. Brains were examined microscopically for evidence of neuronal vacuolation (4-6h postdose) and neurodegeneration ( approximately 24 or 48h postdose). Administration of dextromethorphan at 120mg/(kg day) in females, and at > or =150mg/(kg day) in males produced marked behavioral changes, indicative of neurologic effects. Mortality occurred at the highest doses administered. There were no detectable neuropathologic changes following single or repeated oral administration of dextromethorphan at any dose. Administration of MK-801 (9mg/kg) produced both cytoplasmic vacuolation and neuronal degeneration in neurons of the RS/PC cortex. Thus characteristic neuropathologic changes found with more potent NMDA receptor antagonists do not occur following single or repeated oral administration of dextromethorphan.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neuro.2007.03.009DOI Listing

Publication Analysis

Top Keywords

administration dextromethorphan
16
oral administration
12
nmda receptor
12
neuropathologic changes
12
dextromethorphan
8
neuronal vacuolation
8
receptor antagonists
8
female rats
8
single repeated
8
repeated oral
8

Similar Publications

Safety, bactericidal activity, and pharmacokinetics of the antituberculosis drug candidate BTZ-043 in South Africa (PanACEA-BTZ-043-02): an open-label, dose-expansion, randomised, controlled, phase 1b/2a trial.

Lancet Microbe

December 2024

Institute of Infectious Diseases and Tropical Medicine, LMU University Hospital, LMU Munich, Germany; German Center for Infection Research, Munich Partner Site, Munich, Germany; Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology, Infection, and Pandemic Research, Munich, Germany; Unit Global Health, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany. Electronic address:

Background: The broad use of bedaquiline and pretomanid as the mainstay of new regimens to combat tuberculosis is a risk due to increasing bedaquiline resistance. We aimed to assess the safety, bactericidal activity, and pharmacokinetics of BTZ-043, a first-in-class DprE1 inhibitor with strong bactericidal activity in murine models.

Methods: This open-label, dose-expansion, randomised, controlled, phase 1b/2a trial was conducted in two specialised tuberculosis sites in Cape Town, South Africa.

View Article and Find Full Text PDF

Post-stroke effects of IC87201 on neurobehavioral function and brain injuries: A stereological study.

IBRO Neurosci Rep

December 2024

Histomorphometry and Stereology Research Center and Department of Anatomical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran.

Article Synopsis
  • Stroke is a major global health issue, mainly causing neuron death through NMDA receptor overactivation, and this study explores IC87201 as a potential treatment to reduce brain damage from ischemic strokes.
  • In an experiment with 24 male rats subjected to cerebral ischemia, researchers compared the effects of IC87201 and Dextromethorphan hydrobromide (DXM) on post-stroke brain recovery.
  • Results indicate that IC87201 significantly improved neurobehavioral functions and reduced brain damage more effectively than DXM, particularly enhancing cell survival in the striatum area of the brain.
View Article and Find Full Text PDF
Article Synopsis
  • * Brexpiprazole is the only approved drug for agitation in Alzheimer's, but its effectiveness is questioned, and there are no approved treatments for psychosis, emphasizing the urgent need for new therapies.
  • * The review identifies three promising compounds in phase 3 trials for treating these symptoms: xanomeline-trospium for psychosis, and dextromethorphan-bupropion and dexmedetomidine for agitation; it also suggests incorporating biomarkers in clinical trials to improve drug testing efficiency.
View Article and Find Full Text PDF

Clinical and Physiologically Based Pharmacokinetic Model Evaluations of Adagrasib Drug-Drug Interactions.

Clin Pharmacol Ther

November 2024

Clinical Pharmacology and Nonclinical Development, Mirati Therapeutics Inc. (A Bristol Myers Squib Company), San Diego, California, USA.

Adagrasib is a potent, highly selective, orally available, small molecule, covalent inhibitor of G12C mutated KRAS. As both a substrate and strong inhibitor of cytochrome P450 (CYP) 3A4, adagrasib inhibits its own CYP3A4-mediated metabolism following multiple dosing, resulting in time-dependent drug-drug interaction (DDI) liabilities. A physiologically-based pharmacokinetic (PBPK) model was developed and verified using a combination of physicochemical, in vitro and clinical pharmacokinetic (PK) data from healthy volunteers and cancer patients.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!